What would you like to look for?
Site search
Search filters

Fangda Carbon New Material Co., Ltd. completes GDR Offering and Listing on SIX Swiss Exchange

16 March 2023

Fangda Carbon New Material Co., Ltd., an integrated carbon materials producer in in the People's Republic of China with diversified product offerings, including graphite electrodes, carbon blocks, isostatic graphite and iron ore concentrates, sold 22m global depositary receipts (GDRs) at an offer price of USD 8.63 per GDR and listed on 15 March 2023 a total number of 57'089'555 GDRs on the SIX Swiss Exchange (ISIN: US30712D1072, ticker: FDCB), thereby successfully tapping the Swiss capital market and raising gross proceeds of approximately USD 190m. Each GDR represents ten A shares of Fangda, which in turn are listed on the Shanghai Stock Exchange (600516.SH).

Hangzhou GreatStar Industrial lists GDRs on SIX Swiss Exchange

22 November 2022

On 15 November 2022, Hangzhou GreatStar Industrial Co., Ltd., whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX Swiss Exchange.

Ningbo Shanshan raises USD 310.5 million through GDRs issuance and listing on the SIX Swiss Exchange

28 July 2022

On 28 July 2022, Ningbo Shanshan Co. raised USD 310.5m through GDRs issuance and listing on the SIX Swiss Exchange.

Novaremed and NeuroFront enter option and license agreement for NRD.E1

25 July 2022

Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.

Oculis closes an oversubscribed USD 57m Series C financing round

6 May 2021

Oculis S.A., a late-stage biopharmaceutical company, focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, has closed an oversubscribed USD 57m Series C financing round.

CITIC becomes largest shareholder in MedAlliance

22 March 2021

Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, has completed its over USD 50.0m investment in the Switzerland based global leading medical technology company MedAlliance SA ("MedAlliance"), becoming MedAlliance's single largest shareholder.

Polyphor grants Fosun Pharma license for balixafortide in China

2 September 2020

Polyphor AG (SIX: POLN) and Shanghai Fosun Pharmaceutical (Group) Co. Ltd ("Fosun Pharma", stock code: 600196.SH; 02196.HK), through its Swiss affiliate Fosun Pharmaceutical AG entered into an exclusive licensing agreement for...

Sale of Lamina Technologies SA to Triton

4 June 2020

Lamina Technologies SA acquired by Triton: The Yverdon based multi material cutting tools development company Lamina Technologies SA ("Lamina") was acquired on 14 May 2020 by Triton through its Triton Smaller Mid Cap Fund ("TSM")....

Numab and Sunshine Guojian form partnership

20 December 2019

3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...

NUMAB concludes Licensing and Development Agreement in China

2 May 2019
29 April 2019

Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and...